HomeClinical Trials Update

Clinical Trials Update

FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment...

The U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) from ADC Therapeutics for loncastuximab...

Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize Mirvetuximab Soravtansine

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in...

IMGN632 Receives Breakthrough Therapy Designation in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632, a novel CD123-targeting Antibody-drug Conjugate...

Cetuximab Saratolacan Approved in Japan for the Treatment of Unresectable Locally Advanced and Recurrent...

Japan’s Ministry of Health, Labour and Welfare has approved cetuximab saratolacan sodium (previously known as RM-1929; Akalux® IV Infusion...

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin in Cervical Cancer

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27% ORR

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics). This is the conclusion from an analysis...

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in Urothelial Cancer

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in Ovarian Cancer

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in HER3 Expressing Advanced...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as...